Browse
Explore clinical trials and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
95043 trials found · Page 150 of 4753
-
New PTSD drug shows promise in large trial
Symptom relief Recruiting nowThis study is evaluating the safety and efficacy of TSND-201 in adults with PTSD. Eligible participants will enter a 4-week Treatment Period where they will be randomized 1:1:1 to receive one of two doses of TSND-201 or placebo, once per week. Following the Treatment Period, par…
Phase: PHASE3 • Sponsor: Transcend Therapeutics • Aim: Symptom relief
Last updated May 13, 2026 15:58 UTC
-
New light gel could save diabetic feet from amputation
Disease control Recruiting nowProtocol No. CHLORIN E6-IIB/III-01/Protocol/1.1 Title:Single-Centre, open-labeled, randomized, Phase IIb and Phase III clinical studies to evaluate the safety, tolerability, and efficacy of Chlorin E6 (Gel Formation) as a photosensitizing agent for the management of Diabetic Foot…
Phase: PHASE3 • Sponsor: United Medical and Dental College • Aim: Disease control
Last updated May 04, 2026 16:20 UTC
-
New blood test could slash unnecessary colonoscopies for colorectal cancer screening
Diagnosis Recruiting nowColorectal cancer is the third most common cancer in men, and the second most common in women. Screening for colorectal cancer is based on the search for blood in the stool using fecal immunochemical test (FIT). Occult bleeding is an indication for colonoscopy. In a FIT positive …
Phase: NA • Sponsor: CHU de Reims • Aim: Diagnosis
Last updated May 15, 2026 11:57 UTC
-
Double-barreled cell therapy takes aim at hard-to-treat blood cancers
Disease control Not yet recruitingThis is a single arm study to evaluate the safety and efficacy of CAR19BCMA CAR-T cells in the treatment of relapsed/refractory CD19/BCMA positive plasma cell neoplasms and lymphomas/leukemias with plasmacytic differentiation.
Phase: EARLY_PHASE1 • Sponsor: Affiliated Hospital to Academy of Military Medical Sciences • Aim: Disease control
Last updated May 16, 2026 06:51 UTC
-
New hope for HAE patients: extension study tests long-term attack prevention
Disease control Recruiting nowStudy ADX-324-302 is an extension study for participants who complete the Phase 3 ADX-324-301 trial. The extension study will provide information about the safety and efficacy of additional dosing of ADX-324 in participants with Type I and Type II hereditary angioedema (HAE). The…
Phase: PHASE3 • Sponsor: ADARx Pharmaceuticals, Inc. • Aim: Disease control
Last updated May 14, 2026 12:04 UTC
-
Smart insulin system may help kids with new diabetes avoid Long-Term problems
Disease control Not yet recruitingThe purpose of this study is to investigate the effect of early initiated automated insulin de-livery (AID) treatment in type diabetes in children aged 7-16 years to glycemic control, diabe-tes distress of patients and caregivers, long-term micro- and macrovascular complications …
Phase: NA • Sponsor: Helsinki University Central Hospital • Aim: Disease control
Last updated May 07, 2026 18:43 UTC
-
New hope for pancreatic cancer: targeted drug combo enters phase 3 trial
Disease control Recruiting nowThis phase III trial compares the effect of adding panitumumab to standard chemotherapy (with nanoliposomal Irinotecan, leucovorin, and 5-fluorouracil \[5-FU\] or irinotecan, leucovorin, and 5-FU or nab-paclitaxel and gemcitabine) versus standard chemotherapy alone in treating pa…
Phase: PHASE3 • Sponsor: SWOG Cancer Research Network • Aim: Disease control
Last updated May 16, 2026 06:49 UTC
-
Magic mushroom therapy targets Cancer's hidden toll: despair
Symptom relief Recruiting nowDemoralization syndrome is frequently present in palliative care and oncology patients. In particular, up to a third of patients diagnosed with cancer will experience demoralization due to their illness. The relevance of demoralization syndrome in oncology is tied to this syndrom…
Phase: PHASE1 • Sponsor: Gustavo Vazquez • Aim: Symptom relief
Last updated May 15, 2026 11:54 UTC
-
New combo therapy aims to boost immune attack on Hard-to-Treat colorectal cancer
Disease control Not yet recruitingThe goal of this clinical trial is to learn whether a high- and low-dose radiotherapy regimen followed by anti-angiogenic TKI and anti-PD-1 antibody therapy works to treat advanced metastatic colorectal cancer. It will also evaluate long-term survival outcomes and explore potenti…
Phase: PHASE2 • Sponsor: Daping Hospital and the Research Institute of Surgery of the Third Military Medical University • Aim: Disease control
Last updated May 13, 2026 16:03 UTC
-
New drug aims to tackle high blood pressure and obesity together
Disease control Not yet recruitingA multicenter, randomized, double-blind, placebo-controlled clinical study to evaluate the efficacy and safety of IBI362 in participants with mild to moderate hypertension complicated by overweight/obesity who have not received antihypertensive drug treatment
Phase: PHASE3 • Sponsor: Innovent Biologics (Suzhou) Co. Ltd. • Aim: Disease control
Last updated May 14, 2026 12:05 UTC
-
New hope for lymphoma patients: drug may keep cancer in check
Disease control Not yet recruitingThis is a prospective, multicenter, single-arm, open-label phase 2 study designed to evaluate the efficacy and safety of chidamide maintenance in adults with newly diagnosed double-expressor diffuse large B-cell lymphoma (DLBCL) who achieve complete response after induction thera…
Phase: PHASE2 • Sponsor: Rong Tao • Aim: Disease control
Last updated May 16, 2026 06:49 UTC
-
New hope for elderly blood cancer patients: tailored transplant approach shows promise
Disease control Recruiting nowAcute myeloid leukemia (AML) is one of the most common hematologic malignancies. With increasing life expectancy and the aging of society, the incidence of AML in the elderly population is rising. The prognosis of elderly AML patients is significantly worse than that of younger p…
Phase: NA • Sponsor: The First Affiliated Hospital of Soochow University • Aim: Disease control
Last updated May 16, 2026 06:51 UTC
-
Kidney-Sparing combo therapy aims to beat cancer without losing the organ
Disease control Not yet recruitingUTUC is a cancer that develops in the lining of the kidney or ureter. The standard treatment is radical nephroureterectomy, which removes the kidney and ureter. Although this surgery can control the cancer, it permanently reduces kidney function. Endoscopic treatment can serve a…
Sponsor: Peking University First Hospital • Aim: Disease control
Last updated May 15, 2026 11:54 UTC
-
New drug may unlock transplants for Hard-to-Match kidney patients
Disease control Not yet recruitingThe goal of this clinical trial is to determine whether belimumab can improve detection of circulating HLA-specific memory B cells to support safer and more effective donor organ allocation in highly sensitized kidney transplant candidates. The main questions it aims to answer a…
Phase: PHASE2 • Sponsor: Leiden University Medical Center • Aim: Disease control
Last updated May 15, 2026 11:57 UTC
-
Could a diabetes drug curb alcohol cravings and save livers?
Disease control Recruiting nowBackground: People with alcohol use disorder (AUD) often develop metabolic alcohol-associated liver disease (MetALD). MetALD is a term for the heart, liver, obesity, and other issues that can accompany AUD. MetALD can be fatal. An approved weight management drug (Tirzepatide) ma…
Phase: PHASE2 • Sponsor: National Institute on Alcohol Abuse and Alcoholism (NIAAA) • Aim: Disease control
Last updated May 07, 2026 18:43 UTC
-
Can a herbal capsule slash liver cancer risk in hepatitis b patients?
Disease control Not yet recruitingThis study aims to establish a prospective, multicenter, randomized, double-blind, placebo-controlled parallel-group clinical trial cohort. The cohort will include high-risk populations for hepatitis B cirrhosis-related hepatocellular carcinoma (HCC) from multiple centers nationw…
Phase: NA • Sponsor: Nanfang Hospital, Southern Medical University • Aim: Disease control
Last updated May 16, 2026 06:52 UTC
-
New hope for stubborn lung cancer: drug duo targets STK11 mutation
Disease control Recruiting nowThis phase II trial tests how well GT103 in combination with pembrolizumab works in treating patients with STK11 mutant non-small cell lung cancer that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced) or that has s…
Phase: PHASE2 • Sponsor: Roswell Park Cancer Institute • Aim: Disease control
Last updated May 06, 2026 16:03 UTC
-
Glow-in-the-Dark scanner could slash repeat breast cancer surgeries
Diagnosis Not yet recruitingThe goal of this clinical trial is to learn if a novel intraoperative fluorescence-guided system (EndoSCell Scanner) can help surgeons more accurately remove all cancerous tissue during breast-conserving surgery in female patients aged 18 years or older, with primary breast cance…
Phase: NA • Sponsor: Guangdong Provincial People's Hospital • Aim: Diagnosis
Last updated May 14, 2026 12:06 UTC
-
New hope for hard-to-treat breast cancer: SYS6010 enters phase 3 trial
Disease control Not yet recruitingThis study is a multicenter, randomized, open-label, parallel-control Phase III clinical trial enrolling patients with unresectable HER2-negative, EGFR-positive recurrent/metastatic breast cancer who have previously failed first- or second-line chemotherapy. It aims to compare th…
Phase: PHASE3 • Sponsor: CSPC Megalith Biopharmaceutical Co.,Ltd. • Aim: Disease control
Last updated May 08, 2026 12:04 UTC
-
New hope for elderly lymphoma patients: triple-drug combo targets aggressive cancer
Disease control Not yet recruitingThis is a single-arm, prospective, multicenter, open-label phase Ib/II study to evaluate the safety and efficacy of polatuzumab vedotin in combination with rituximab and chidamide in previously untreated elderly patients with MYC/BCL2 double-expressor diffuse large B-cell lymphom…
Phase: PHASE1, PHASE2 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated May 11, 2026 20:49 UTC